This guarantees quality and safety and can restrict availability in certain areas
Please note that while the facility we partner with is FDA-registered, the compounded medications themselves are not FDA-approved
Robinson LE, Holt TA, Rees K, Randeva HS, OHare JP
Private and Self-Pay Arrangements Lead Treatment Access in South Korea In South Korea, the market is expected to remain dominated by private insurance and self-pay arrangements, which hold an 85% share in 2025
Saxenda has higher rates of gastrointestinal side effects than either and requires daily rather than weekly injections
The weight loss and lipid profile benefits seen among participants underscored retatrutides potential to improve broader metabolic and cardiovascular risk